zoledronic acid
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Malignant Pleural Effusion
Conditions
Malignant Pleural Effusion, Non Small Cell Lung Cancer
Trial Timeline
Nov 1, 2009 → Apr 1, 2011
NCT ID
NCT01004510About zoledronic acid
zoledronic acid is a phase 2 stage product being developed by Novartis for Malignant Pleural Effusion. The current trial status is terminated. This product is registered under clinical trial identifier NCT01004510. Target conditions include Malignant Pleural Effusion, Non Small Cell Lung Cancer.
What happened to similar drugs?
5 of 20 similar drugs in Malignant Pleural Effusion were approved
Approved (5) Terminated (2) Active (13)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01197300 | Phase 3 | Completed |
| NCT01087008 | Approved | Completed |
| NCT01004510 | Phase 2 | Terminated |
| NCT00909961 | Phase 3 | Completed |
| NCT00966992 | Phase 2 | Terminated |
| NCT00760370 | Phase 2 | Completed |
| NCT00774020 | Approved | Completed |
| NCT00740129 | Approved | Completed |
| NCT00745485 | Approved | Completed |
| NCT00477217 | Phase 2 | Withdrawn |
| NCT00622505 | Approved | Completed |
| NCT00982124 | Phase 3 | Completed |
| NCT01218035 | Approved | Completed |
| NCT00434447 | Approved | Completed |
| NCT00424983 | Phase 1 | Completed |
| NCT00391950 | Phase 3 | Terminated |
| NCT00361595 | Pre-clinical | Completed |
| NCT00334139 | Approved | Completed |
| NCT00391690 | Approved | Completed |
| NCT00375427 | Phase 3 | Completed |
Competing Products
20 competing products in Malignant Pleural Effusion